2022 Pivotal Points in Pediatric Atopic Dermatitis: What You Probably Missed But Shouldn’t Have Pretest

1. What is your degree?

2. What is your specialty?

3. How confident are you in the management of patients with pediatric AD in your practice?

4. How confident do you feel in treating pediatric patients with newly approved therapies?

5. Noah, a 26-month-old boy, presents with AD that he was diagnosed with 3 months ago. Noah’s skin is excoriated in places because of scratching and his mother reports that he cries much more than other 2-year-olds, doesn’t nap at all, or sleep more than 2 or 3 hours at a time throughout the night. This has had a negative impact on the entire family. There has been minimal response to high-dose topical corticosteroid with emollients and wet wraps. Noah may be an ideal candidate for which of the following treatments based on recent clinical trial data?

6. Which non-cutaneous effects associated with pediatric AD can have negative long-term quality of life consequences?

7. In the clinical trials of JAK inhibitors for adolescents with moderate to severe AD (oral upadacitinib and topical ruxolitinib), which were the most common treatment-emergent adverse events reported across trials for both agents?

8. Of the four emerging JAK inhibitors in phase 3 clinical trials in pediatric AD, which is being studied in the youngest cohort comprising ages 2–11 years?